Literature DB >> 10923356

Disturbances of acid-base balance and bone disease in end-stage renal disease.

J A Kraut1.   

Abstract

Bone disease in patients with chronic renal failure (CRF) is thought to be the consequence primarily of the interplay of several factors, including the serum levels of parathyroid hormone (PTH), vitamin D, calcium, and phosphorus, and exposure to bone toxins such as aluminum or amyloid. Recently the metabolic acidosis noted with CRF has been implicated as an additional factor contributing to the genesis of bone disease. Although metabolic acidosis might be the dominant factor in the cause of bone disease in some instances, more commonly this acid-base disturbance interacts with other factors contributing to the development of bone disease. The following article summarizes the data in support of an important role for metabolic acidosis in the genesis of bone disease in patients with CRF and presents our recommendations for treatment of uremic acidosis to prevent or treat the bone disease.

Entities:  

Mesh:

Year:  2000        PMID: 10923356     DOI: 10.1046/j.1525-139x.2000.00070.x

Source DB:  PubMed          Journal:  Semin Dial        ISSN: 0894-0959            Impact factor:   3.455


  9 in total

Review 1.  Correction of chronic metabolic acidosis for chronic kidney disease patients.

Authors:  P Roderick; N S Willis; S Blakeley; C Jones; C Tomson
Journal:  Cochrane Database Syst Rev       Date:  2007-01-24

2.  Correction of metabolic acidosis in hemodialysis: consequences on serum leptin and mineral metabolism.

Authors:  Alessandra M Bales; Rosa M A Moysés; Luciene M dos Reis; Fabiana G Graciolli; James Hung; Manuel Carlos Martins Castro; Rosilene M Elias
Journal:  Int Urol Nephrol       Date:  2014-09-25       Impact factor: 2.370

Review 3.  Metabolic acidosis: pathophysiology, diagnosis and management.

Authors:  Jeffrey A Kraut; Nicolaos E Madias
Journal:  Nat Rev Nephrol       Date:  2010-03-23       Impact factor: 28.314

4.  Urinary ammonia and long-term outcomes in chronic kidney disease.

Authors:  Marion Vallet; Marie Metzger; Jean-Philippe Haymann; Martin Flamant; Cédric Gauci; Eric Thervet; Jean-Jacques Boffa; François Vrtovsnik; Marc Froissart; Bénédicte Stengel; Pascal Houillier
Journal:  Kidney Int       Date:  2015-03-11       Impact factor: 10.612

Review 5.  Consequences and therapy of the metabolic acidosis of chronic kidney disease.

Authors:  Jeffrey A Kraut; Nicolaos E Madias
Journal:  Pediatr Nephrol       Date:  2010-06-05       Impact factor: 3.714

Review 6.  Acidosis: progression of chronic kidney disease and quality of life.

Authors:  Ione de-Brito Ashurst; Emma O'Lone; Tarun Kaushik; Kieran McCafferty; Muhammad M Yaqoob
Journal:  Pediatr Nephrol       Date:  2014-08-02       Impact factor: 3.714

7.  Varying Dialysate Bicarbonate Concentrations in Maintenance Hemodialysis Patients Affect Post-dialysis Alkalosis but not Pre-dialysis Acidosis.

Authors:  U-Seok Noh; Joo-Hark Yi; Sang-Woong Han; Ho-Jung Kim
Journal:  Electrolyte Blood Press       Date:  2007-12-31

8.  Acetate free citrate-containing dialysate increase intact-PTH and BAP levels in the patients with low intact-PTH.

Authors:  Takahiro Kuragano; Minoru Furuta; Mana Yahiro; Aritoshi Kida; Yoshinaga Otaki; Yukiko Hasuike; Akihide Matsumoto; Takeshi Nakanishi
Journal:  BMC Nephrol       Date:  2013-01-18       Impact factor: 2.388

9.  Does oral sodium bicarbonate therapy improve function and quality of life in older patients with chronic kidney disease and low-grade acidosis (the BiCARB trial)? Study protocol for a randomized controlled trial.

Authors:  Miles D Witham; Margaret M Band; Roberta C Littleford; Alison Avenell; Roy L Soiza; Marion E T McMurdo; Deepa Sumukadas; Simon A Ogston; Edmund J Lamb; Geeta Hampson; Paul McNamee
Journal:  Trials       Date:  2015-08-01       Impact factor: 2.279

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.